Schering Moves Vicriviroc Phase III Program Forward In HIV
This article was originally published in The Pink Sheet Daily
Company has initiated two Phase III studies of the CCR5 receptor antagonist in treatment-experienced HIV patients.
You may also be interested in...
First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.
Both Schering’s vicriviroc and Incyte’s INCB9471 CCR5 antagonist candidates to treat HIV beat placebo in Phase II trials.
Pfizer expects Comirnaty and Paxlovid revenues to be drastically lower this year after pushing 2022 revenues over $100bn. Management said 2023 would be a transition year for the company.